503 related articles for article (PubMed ID: 25749381)
1. CSIG promotes hepatocellular carcinoma proliferation by activating c-MYC expression.
Cheng Q; Yuan F; Lu F; Zhang B; Chen T; Chen X; Cheng Y; Li N; Ma L; Tong T
Oncotarget; 2015 Mar; 6(7):4733-44. PubMed ID: 25749381
[TBL] [Abstract][Full Text] [Related]
2. miR-451 inhibits cell proliferation in human hepatocellular carcinoma through direct suppression of IKK-β.
Li HP; Zeng XC; Zhang B; Long JT; Zhou B; Tan GS; Zeng WX; Chen W; Yang JY
Carcinogenesis; 2013 Nov; 34(11):2443-51. PubMed ID: 23740840
[TBL] [Abstract][Full Text] [Related]
3. FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.
Zhou JD; Shen F; Ji JS; Zheng K; Huang M; Wu JC
Oncol Rep; 2013 Sep; 30(3):1275-84. PubMed ID: 23836295
[TBL] [Abstract][Full Text] [Related]
4. Orosomucoid 2 inhibits tumor metastasis and is upregulated by CCAAT/enhancer binding protein β in hepatocellular carcinomas.
Fang T; Cui M; Sun J; Ge C; Zhao F; Zhang L; Tian H; Zhang L; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li H; Li J
Oncotarget; 2015 Jun; 6(18):16106-19. PubMed ID: 25965830
[TBL] [Abstract][Full Text] [Related]
5. Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma.
Lei X; Li YF; Chen GD; Ou DP; Qiu XX; Zuo CH; Yang LY
Oncotarget; 2015 Dec; 6(38):40622-41. PubMed ID: 26536663
[TBL] [Abstract][Full Text] [Related]
6. Enhanced NOLC1 promotes cell senescence and represses hepatocellular carcinoma cell proliferation by disturbing the organization of nucleolus.
Yuan F; Zhang Y; Ma L; Cheng Q; Li G; Tong T
Aging Cell; 2017 Aug; 16(4):726-737. PubMed ID: 28493459
[TBL] [Abstract][Full Text] [Related]
7. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma.
Pannem RR; Dorn C; Ahlqvist K; Bosserhoff AK; Hellerbrand C; Massoumi R
Carcinogenesis; 2014 Feb; 35(2):461-8. PubMed ID: 24104553
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma.
Zhang XF; Chao J; Pan QZ; Pan K; Weng DS; Wang QJ; Zhao JJ; He J; Liu Q; Jiang SS; Chen CL; Zhang HX; Xia JC
Oncotarget; 2015 Dec; 6(38):40920-33. PubMed ID: 26506518
[TBL] [Abstract][Full Text] [Related]
9. Stanniocalcin-1 Reduces Tumor Size in Human Hepatocellular Carcinoma.
Yeung BH; Shek FH; Lee NP; Wong CK
PLoS One; 2015; 10(10):e0139977. PubMed ID: 26469082
[TBL] [Abstract][Full Text] [Related]
10. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.
Li GQ; Guo WZ; Zhang Y; Seng JJ; Zhang HP; Ma XX; Zhang G; Li J; Yan B; Tang HW; Li SS; Wang LD; Zhang SJ
Oncotarget; 2016 Jan; 7(3):2462-74. PubMed ID: 26575167
[TBL] [Abstract][Full Text] [Related]
11. CUDR promotes liver cancer stem cell growth through upregulating TERT and C-Myc.
Pu H; Zheng Q; Li H; Wu M; An J; Gui X; Li T; Lu D
Oncotarget; 2015 Dec; 6(38):40775-98. PubMed ID: 26513297
[TBL] [Abstract][Full Text] [Related]
12. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
[TBL] [Abstract][Full Text] [Related]
13. SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression.
Yin J; Ding J; Huang L; Tian X; Shi X; Zhi L; Song J; Zhang Y; Gao X; Yao Z; Jing X; Yang J
Anat Rec (Hoboken); 2013 Oct; 296(10):1568-75. PubMed ID: 23878061
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma.
Shen G; Rong X; Zhao J; Yang X; Li H; Jiang H; Zhou Q; Ji T; Huang S; Zhang J; Jia H
Carcinogenesis; 2014 Dec; 35(12):2748-55. PubMed ID: 25280563
[TBL] [Abstract][Full Text] [Related]
15. NKD1 correlates with a poor prognosis and inhibits cell proliferation by inducing p53 expression in hepatocellular carcinoma.
Zhang S; Li J; Wang X
Tumour Biol; 2016 Oct; 37(10):14059-14067. PubMed ID: 27507614
[TBL] [Abstract][Full Text] [Related]
16. SATB1 and SATB2 play opposing roles in c-Myc expression and progression of colorectal cancer.
Mansour MA; Hyodo T; Akter KA; Kokuryo T; Uehara K; Nagino M; Senga T
Oncotarget; 2016 Jan; 7(4):4993-5006. PubMed ID: 26701851
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the GNMT-HectH9-PREX2 tripartite relationship in the pathogenesis of hepatocellular carcinoma.
Li CH; Yen CH; Chen YF; Lee KJ; Fang CC; Zhang X; Lai CC; Huang SF; Lin HK; Arthur Chen YM
Int J Cancer; 2017 May; 140(10):2284-2297. PubMed ID: 28205209
[TBL] [Abstract][Full Text] [Related]
18. Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma.
Chiba T; Saito T; Yuki K; Zen Y; Koide S; Kanogawa N; Motoyama T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Otsuka M; Miyazaki M; Iwama A; Yokosuka O
Int J Cancer; 2015 Jan; 136(2):289-98. PubMed ID: 24844570
[TBL] [Abstract][Full Text] [Related]
19. Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein.
Dong C; Zhao B; Long F; Liu Y; Liu Z; Li S; Yang X; Sun D; Wang H; Liu Q; Liang R; Li Y; Gao Z; Shao S; Miao QR; Wang L
Oncotarget; 2016 Feb; 7(8):8850-65. PubMed ID: 26840457
[TBL] [Abstract][Full Text] [Related]
20. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
